Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer | Norris Cotton Cancer Center
Skip to main content
x
Norris Cotton Cancer Center
In This Section
 
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer
Principal Investigator (?)
Study Number
F17176
Summary
A phase 2 study to evaluate the efficacy of niraparib alone and in combination with PD-1 inhibitor in three cohorts: all histologies with high PD-L1 expression (greater than 50% TPS), all histologies low PD-L1 expression (1-49% TPS), and squamous cell lung cancer. [TPS=Tumor Proportion Score] 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.

0